Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, single-arm, open-label, Phase 1 study to assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03009344
Study type Interventional
Source Eisai Inc.
Status Active, not recruiting
Phase Phase 1
Start date January 23, 2017
Completion date September 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03664635 - MB-CART20.1 Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03456726 - Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation Phase 2